Ambassador Extraordinary and Plenipotentiary of Uzbekistan to the UK, Ravshan Usmanov, recently met with Nitin Kapoor, Deputy Head of Production Expansion at AstraZeneca, to explore avenues for collaboration between Uzbekistan and the British-Swedish pharmaceutical and biotechnology giant.
During the meeting, Nitin Kapoor provided an overview of AstraZeneca’s global operations, highlighting the company’s ongoing research into innovative treatments for major diseases such as cancer, cardiovascular conditions, and respiratory disorders. Kapoor reiterated AstraZeneca’s commitment to expanding its footprint in Uzbekistan, taking advantage of the country’s burgeoning pharmaceutical industry.
Ambassador Usmanov discussed the comprehensive reforms underway in Uzbekistan’s pharmaceutical sector, designed to attract foreign investment and enhance local production capabilities. He emphasized the benefits available to foreign investors, including the development of new production facilities and a supportive business environment. These reforms are intended to create an ideal setting for AstraZeneca to further expand its presence in Uzbekistan.
The meeting concluded with both parties agreeing to continue strengthening bilateral relations through future meetings and visits, signaling a promising collaboration between Uzbekistan and AstraZeneca.
Founded in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group, AstraZeneca is headquartered at the Cambridge Biomedical Campus in the UK and employs around 90,000 people globally. The company is renowned for its research and production of medicines targeting critical health issues such as cancer, cardiovascular diseases, gastrointestinal disorders, infectious diseases, neurological conditions, respiratory problems, and inflammatory diseases.
